Search alternatives:
marked decrease » marked increase (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
key decrease » we decrease (Expand Search), teer decrease (Expand Search), step decrease (Expand Search)
five » file (Expand Search)
Showing 1 - 20 results of 7,265 for search '(( five ((key decrease) OR (mean decrease)) ) OR ( i ((large decrease) OR (marked decrease)) ))', query time: 0.70s Refine Results
  1. 1
    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection.

    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

    Published 2024
    Save to List
    Saved in:
  2. 2
    Expression of lipid biosynthetic genes is decreased with polyamine depletion.

    Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

    Published 2024
    Save to List
    Saved in:
  3. 3
    The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT).

    The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

    Published 2025
    Save to List
    Saved in:
  4. 4
    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU.

    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Conditional knockout of SLAMF5 in CX3CR1<sup>er</sup> cells attenuates EAE progression, reduces brain myeloid cell activation, and decreases T cell infiltration.

    Conditional knockout of SLAMF5 in CX3CR1<sup>er</sup> cells attenuates EAE progression, reduces brain myeloid cell activation, and decreases T cell infiltration. by Laura Bellassen (22209109)

    Published 2025
    Save to List
    Saved in:
  6. 6
    Tetrandrine decreases Mtb antigen presentation.

    Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

    Published 2025
    Save to List
    Saved in:
  7. 7
    <i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages.

    <i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

    Published 2024
    Save to List
    Saved in:
  8. 8
    NSC population and proliferation decrease drastically during the second postnatal week of DG development.

    NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

    Published 2025
    Save to List
    Saved in:
  9. 9
    Maximum IFN concentrations are decreased in severe patients.

    Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

    Published 2025
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: